Advances in molecular biomarkers for gastric cancer: MiRNAs as emerging novel cancer markers

Expert Reviews in Molecular Medicine

Volumn 16, Issue , 2014, Pages

  Wu, Hua Hsi ^a,b   Lin, Wen Chang ^a,c   Tsai, Kuo Wang ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; COMPLEMENTARY DNA; MICRORNA; MICRORNA 1; MICRORNA 106A; MICRORNA 10B; MICRORNA 129; MICRORNA 196A; MICRORNA 20A; MICRORNA 21; MICRORNA 221; MICRORNA 27A; MICRORNA 34; MICRORNA 376C; MICRORNA 378; MICRORNA 421; MICRORNA 423 5P; PEPSINOGEN I; PEPSINOGEN II; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE PROGRESSION; DISEASE MARKER; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENOME ANALYSIS; HUMAN; MARKER GENE; MOLECULAR DIAGNOSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; STOMACH CANCER; SYSTEMS BIOLOGY; TISSUE DISTRIBUTION; ADENOCARCINOMA; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; STOMACH TUMOR;

ADENOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; RNA INTERFERENCE; STOMACH NEOPLASMS; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 84915756694     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2013.16     Document Type: Review

References (128)

1. Hartgrink, H.H. et al. (2009) Gastric cancer. Lancet 374, 477-490
2. Wu, C.W. et al. (2006) Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncology 7, 309-315
3. Wu, C.W. et al. (2000) Surgical mortality, survival, and quality of life after resection for gastric cancer in the elderly. World Journal of Surgery 24, 465-72
4. Sharma, M.R. and Schilsky, R.L. (2011) GI cancers in 2010: new standards and a predictive biomarker for adjuvant therapy. Nature Reviews Clinical Oncology 8, 70-72
5. Smyth, E.C. and Cunningham, D. (2013) Gastric cancer in 2012: defining treatment standards and novel insights into disease biology.Nature Reviews Clinical Oncology 10, 73-74
6. Dassen, A.E. et al. (2010) Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. European Journal of Cancer 46, 1101-1110
7. Oba, K. et al. (2013) Role of chemotherapy for advanced/recurrent gastric cancer: an individualpatient- data meta-analysis. European Journal of Cancer 49, 1565-1577
8. Gonzalez, C.A. and Agudo, A. (2012) Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. International Journal of Cancer 130, 745-753
9. He, C.Z. et al. (2013) Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterology 13, 87
10. Jiexian, J. et al. (2013) Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer. International Journal of Biological Markers 28, 192-200
11. Lai, I.R. et al. (2002) Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 49, 1157-1160
12. Nam, D.H. et al. (2013) Prognostic value of early postoperative Tumor Marker response in gastric cancer. Ann Surg Oncol 20, 3905-3911
13. Denk, H. et al. (1972) Carcinoembryonic antigen (CEA) in gastrointestinal and extragastrointestinal tumors and its relationship to tumor-cell differentiation. International Journal of Cancer 10, 262-272
14. Emoto, S. et al. (2012) Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 15, 154-161
15. Li, Y. et al. (2011) Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology 58, 2166-2170
16. Mukoubayashi, C. et al. (2007) Serum pepsinogen and gastric cancer screening. Internal Medicine 46, 261-266
17. Correia, M. et al. (2009) Basic aspects of gastric cancer. Helicobacter 14 Suppl 1, 36-40
18. Hamashima, C. et al. (2008) The Japanese guidelines for gastric cancer screening. Japanese Journal of Clinical Oncology 38, 259-267
19. Keller, G. et al. (2005) Molecular medicine of gastric adenocarcinomas. Expert Reviews in Molecular Medicine 7, 1-13
20. Leung,W.K. et al. (2008) Screening for gastric cancer in Asia: current evidence and practice. The Lancet Oncology 9, 279-287
21. Nobili, S. et al. (2011) Genomic and genetic alterations influence the progression of gastric cancer. World Journal of Gastroenterology 17, 290-299
22. Song, B. and Ju, J. (2010) Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. Expert Reviews in Molecular Medicine 12, e33
23. David, S. and Meltzer, S.J. (2010) Stomach - genetic and epigenetic alterations of preneoplastic and neoplastic lesions. Cancer Biomarks 9, 493-507
24. Hudler, P. (2012) Genetic aspects of gastric cancer instability. Scientific World Journal 2012: 761909
25. Janjigian, Y.Y. and Kelsen, D.P. (2013) Genomic dysregulation in gastric tumors. Journal of Surgery Oncology 107, 237-242
26. Jang, B.G. and Kim, W.H. (2011) Molecular pathology of gastric carcinoma. Pathobiology 78, 302-310
27. Milne, A.N. et al. (2009) Nature meets nurture: molecular genetics of gastric cancer. Human Genetics 126, 615-628
28. Smith, M.G. et al. (2006) Cellular and molecular aspects of gastric cancer. World Journal of Gastroenterology 12, 2979-2990
29. Tahara, E. (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157, 327-349
30. Yamashita, K. et al. (2011) Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surgery Today 41, 24-38
31. Yasui, W. et al. (2011) Molecular pathology of gastric cancer: research and practice. Pathology - Research and Practice 207, 608-612
32. Tan, I.B. et al. (2012) Understanding the genetic basis of gastric cancer: recent advances. Expert Reviews in Gastroenterology and Hepatology 6, 335-341
33. Wu, C.W. et al. (2002) Gastric cancer: prognostic and diagnostic advances. Expert Reviews in Molecular Medicine 2002, 1-12
34. Lin, J.S. et al. (1998) Protein-tyrosine kinase and protein-serine/ threonine kinase expression in human gastric cancer cell lines. Journal of Biomedical Science 5, 101-110
35. Lin, W. et al. (2000) Tyrosine kinases and gastric cancer. Oncogene 19, 5680-5689
36. Wu, C.W. et al. (2006) Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Letters 242, 95-103
37. Lin,W.C. et al. (1999) tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 5, 1745-1751
38. Wu, C.W. et al. (2000) Human gastric cancer kinase profile and prognostic significance ofMKK4kinase. American Journal of Pathology 156, 2007-2015
39. Wu, C.W. et al. (2002) Clinical significance of AXL kinase family in gastric cancer. Anticancer Research 22, 1071-1078
40. Wu, C.W. et al. (2003) Arg tyrosine kinase expression in human gastric adenocarcinoma is associated with vessel invasion. Anticancer Research 23, 205-210
41. Kao, H.W. et al. (2003) Tyrosine-kinase expression profiles in human gastric cancer cell lines and their modulations with retinoic acids. British Journal of Cancer 88, 1058-1064
42. Weichert, W. et al. (2006) Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Science 97, 271-276
43. Aung, P.P. et al. (2006) Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25, 2546-2557
44. DeRisi, J. et al. (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics 14, 457-460
45. Alizadeh, A.A. et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511
46. Cho, J.Y. et al. (2011) Gene expression signaturebased prognostic risk score in gastric cancer. Clinical Cancer Research 17, 1850-1857
47. Cui, J. et al. (2011)An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Research 39, 1197-1207
48. Hippo, Y. et al. (2002) Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Research 62, 233-240
49. Tan, I.B. et al. (2011) Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141, 476-485, 85 e1-11
50. Sousa, J.F. et al. (2012) Proteomic profiling of paraffin-embedded samples identifies metaplasiaspecific and early-stage gastric cancer biomarkers. American Journal of Pathology 181, 1560-1572
51. Qiu, F.M. et al. (2009) Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. Journal of Experimental and Clinical Cancer Research 28, 126
52. Zang, Z.J. et al. (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nature Genetics 44, 570-574
53. Wang, K. et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature Genetics 43, 1219-1223
54. Zang, Z.J. et al. (2011) Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Research 71, 29-39
55. Liang, H. and Kim, Y.H. (2012) Identifying molecular drivers of gastric cancer through nextgeneration sequencing. Cancer Lett 340, 241-246
56. Kim, Y.H. et al. (2012) AMPKalpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Research 72, 2512-2521
57. Trapnell, C. et al. (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature Protocols 7, 562-578
58. Trapnell, C. et al. (2013) Differential analysis of gene regulation at transcript resolution with RNA-seq. Nature Biotechnology 31, 46-53
59. Kobayashi, Y. et al. (2010) Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer. Hepatogastroenterology 57, 1631-1634
60. Mitani, Y. et al. (2007) Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 26, 4383-4393
61. Chin, L. et al. (2011) Cancer genomics: from discovery science to personalized medicine. Nature Medicine 17, 297-303
62. Liao, Y.L. et al. (2012) Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells. Carcinogenesis 33, 760-769
63. Tsai, K.W. et al. (2010) Epigenetic regulation of miR- 196b expression in gastric cancer. Genes, Chromosomes and Cancer 49, 969-980
64. Tsai, K.W. et al. (2012) Aberrant expression of miR- 196a in gastric cancers and correlation with recurrence. Genes, Chromosomes and Cancer 51, 394-401
65. Wu, W.K. et al. (2010) MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29, 5761-5771
66. Song, J.H. and Meltzer, S.J. (2012) MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143, 35-47 e2
67. Zhang, Z. et al. (2008) miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Laboratory Investigation 88, 1358-1366
68. Zhu, L.H. et al. (2010) MicroRNA-23a promotes the growth of gastric adenocarcinoma cell lineMGC803 and downregulates interleukin-6 receptor. FEBS J 277, 3726-3734
69. Lai, K.W. et al. (2010) MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. European Journal of Cancer 46, 1456-1463
70. Kim, Y.K. et al. (2009) Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Research 37, 1672-1681
71. Zhang, Y. et al. (2012) Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-beta signalling pathway. Nucleic Acids Research 40, 9286-9297
72. Liu, T. et al. (2009) MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Letters 273, 233-242
73. Korpal, M. et al. (2008) The miR-200 family inhibits epithelial- mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Journal of Biological Chemistry 283, 14910-14914
74. Ahn, S.M. et al. (2012) Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene 31, 3051-3059
75. Jin, Z. et al. (2011) MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 30, 1577-1585
76. Lo, S.S. et al. (2012) Overexpression of miR-370 and downregulation of its novel target TGFbeta-RII contribute to the progression of gastric carcinoma. Oncogene 31, 226-237
77. Cui, Y. et al. (2011) MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. PLoS ONE 6, e25872
78. Nishida, N. et al. (2011) MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clinical Cancer Research 17, 2725-2733
79. Tsai, K.W. et al. (2011) Epigenetic regulation of miR- 34b and miR-129 expression in gastric cancer. International Journal of Cancer 129, 2600-2610
80. Wu, J. et al. (2010) miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 9, 1809-1818
81. Hashimoto, Y. et al. (2010) Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis 31, 777-784
82. Saito, Y. et al. (2009) Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p withdownregulation of Mcl-1 in human gastric cancer cells. Oncogene 28, 2738-2744
83. Wada, R. et al. (2010) miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. International Journal of Cancer 127, 1106-1114
84. Song, Y.X. et al. (2011) MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Molecular Cancer 10, 1
85. Tsukamoto, Y. et al. (2010) MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Research 70, 2339-2349
86. Ding, L. et al. (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Research 20, 784-793
87. Sun, T. et al. (2011) miR-429 modulates the expression of c-Myc in human gastric carcinoma cells. European Journal of Cancer 47, 2552-2559
88. Oh, H.K. et al. (2011) Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clinical Cancer Research 17, 2657-2667
89. Bou Kheir, T. et al. (2011) miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Molecular Cancer 10, 29
90. Liang, S. et al. (2011) MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS ONE 6, e18409
91. He, X.P. et al. (2012) Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS Journal 279, 4201-4212
92. Carvalho, J. et al. (2012) Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. Journal of Pathology 228, 31-44
93. Tie, J. et al. (2010) MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genetics 6, e1000879
94. Xu, Y. et al. (2012) MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene 31, 1398-1407
95. Rotkrua, P. et al. (2011) MiR-9 down-regulates CDX2 expression in gastric cancer cells. International Journal of Cancer 129, 2611-2620
96. Tsai, K.W. et al. (2011) Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 6, 1189-1197
97. Wan, H.Y. et al. (2010) Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Molecular Cancer 9, 16
98. Zheng, L. et al. (2013) MicroRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS ONE 8, e55719
99. Liu, Z. et al. (2012) miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. International Journal of Oncology 40, 1553-1560
100. Kim, K. et al. (2011) Epigenetic regulation of microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer. Epigenetics 6, 740-751
101. Feng, R. et al. (2010) miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Letters 298, 50-63
102. Otsubo, T. et al. (2011) MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS ONE 6, e16617
103. Guo, S.L. et al. (2011) miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. International Journal of Biological Science 7, 567-574
104. Zheng, B. et al. (2011) MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clinical Cancer Research 17, 7574-7583
105. Kang, W. et al. (2012) Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS ONE 7, e33919
106. Li, X. et al. (2011) miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Molecular Cancer Research 9, 824-833
107. Chen, X. et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research 18, 997-1006
108. Gilad, S. et al. (2008) Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148
109. Mitchell, P.S. et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academyof Sciences of the United States of America 105, 10513-10518
110. Chim, S.S. et al. (2008) Detection and characterization of placental microRNAs in maternal plasma. Clinical Chemistry 54, 482-490
111. Konishi, H. et al. (2012) Detection of gastric cancerassociated microRNAs on microRNA microarray comparing pre- and post-operative plasma. British Journal of Cancer 106, 740-747
112. Li, C. et al. (2012) MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol 20 suppl 3, 397-405
113. Li, B.S. et al. (2012) Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS ONE 7, e41629
114. Liu, R. et al. (2011) A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. European Journal of Cancer 47, 784-791
115. Liu, H. et al. (2012) Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Letters 316, 196-203
116. Song, M.Y. et al. (2012) Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS ONE 7, e33608
117. Tsujiura, M. et al. (2010) Circulating microRNAs in plasma of patients with gastric cancers. British Journal of Cancer 102, 1174-1179
118. Cui, L. et al. (2013) Gastric juice microRNAs as potential biomarkers for the screening of gastric cancer. Cancer 119, 1618-1626
119. Zhang, X. et al. (2012) Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biology 33, 2349-2355
120. Yu, X. et al. (2013) Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Medical Oncology 30, 365
121. Wang, Y.Y. et al. (2013) Clinicopathologic significance of miR-10b expression in gastric carcinoma. Human Pathology 44, 1278-1285
122. Xu, Y. et al. (2012) miR-21 is a promising novel biomarker for lymph node metastasis in patients with gastric cancer. Gastroenterology Research and Practice 2012, 640168
123. Kogo, R. et al. (2011) Clinical significance of miR- 146a in gastric cancer cases. Clinical Cancer Research 17, 4277-4284
124. Li, X. et al. (2010) Survival prediction of gastric cancer by a seven-microRNA signature. Gut 59, 579-585
125. Jiang, J. et al. (2011) Prognostic significance of miR- 181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/ Oxaliplatin. PLoS ONE 6, e23271
126. Ueda, T. et al. (2010) Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncology 11, 136-146
127. Zhang, X. et al. (2011) Combination of hsa-miR 375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Annals of Oncology 22, 2257-2266
128. Yan, Z. et al. (2012) Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS ONE 7, e40037